Zum Inhalt springen

Michael Marks

@drmichaelmarks.bsky.social did:plc:tcnl3lteuyjseti66zxsbuda

NIHR Research Professor Professor of Medicine at LSHTM. Lead for Integrated Academic Training at LSHTM. Consultant in Infectious Diseases at UCLH. Syphilis & STIs, Neglected Tropical Diseases, Emerging Infectious Diseases, Group A Strep, Pragmatic Trials

Bei Bluesky seit

Follower
6.225
Folgt
485
Posts
653
Tage in Ranglisten
0

Zusammenfassung

Michael Marks (@drmichaelmarks.bsky.social) ist seit 10 Oktober 2024 auf Bluesky. Das Konto hat 6.225 Follower, folgt 485 Konten und hat 653 Posts veröffentlicht.

Ranglisten-Platzierungen

Die besten Tage, an denen Posts dieses Kontos in Debyas Tagesliste kamen.

Dieses Konto war noch in keiner Tagesrangliste.

Zuletzt gelikte Posts

Öffentliche Likes aus dem Bluesky-Netzwerk.

  • Nicole Lieberman, PhD@nicolelieberman.bsky.social

    I’ll be hiring technicians, bioinformaticists, data scientists, and postdocs for a very multidisciplinary team. Graduating soon or looking for a job next summer? Please reach out directly if you’re interested in working with me in Nashville!

    Post anzeigen
  • Nicole Lieberman, PhD@nicolelieberman.bsky.social

    I would be remiss not to share that my brilliant husband Josh (not on Bluesky) will also be joining VUMC as the Medical Director of New Technology and Strategy for Vanderbilt Medical labs, and ID diagnostics service chief. He will be looking for a Leishmania genomics-focused postdoc.

    Post anzeigen
  • Nicole Lieberman, PhD@nicolelieberman.bsky.social

    Ok, part two of my exciting news: I’ll be starting my lab as an Assistant Professor of Pediatrics at Vanderbilt next July, focusing on functional genomics of congenital syphilis.

    Post anzeigen
  • Steven Tong@steventong.bsky.social

    How about ESBLs where pip/taz is better than ceftriaxone? I became more supportive of pip/taz when I realised that for patients with likely GNB sepsis pip/taz had probably 95%+ activity compared to around 85% with ceftriaxone. And that's not because of Pseudomonas.

    Post anzeigen
  • Nicole Lieberman, PhD@nicolelieberman.bsky.social

    Absolutely thrilled to share that my NIAID Director’s New Innovator Award (DP2) has been funded. I’ll be using functional genomics, biochemistry, and immunological techniques to understand the mechanisms and drivers of immune evasion by Treponema pallidum, the bacterium that causes syphilis.

    Post anzeigen

Melde dich an, um mehr zu sehen

Blockierte Konten

Blockierungen sind auf Bluesky öffentlich.